FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy

Carlos J. Díaz Osterman(Moores Cancer Center), David D. Schlaepfer(UC San Diego Health System), Isabelle Tancioni(University of California San Diego), Shulin Jiang(Johns Hopkins University), Jyrki Heino(University of Turku), Balázs Győrffy(Semmelweis University), Edward A. Cordasco(Moores Cancer Center), L.M. Bean(Moores Cancer Center), Xiao Lei Chen(Xiamen University), Denise C. Connolly(Fox Chase Cancer Center), Kristen Anderson(Moores Cancer Center), Christine Jean(Centre National de la Recherche Scientifique), Dwayne G. Stupack(University of California San Diego), Kathleen M. Fisch(University of California San Diego), Marjaana Ojalill(University of Turku), Alfredo Molinolo(University of San Diego), Kristin Taylor(Wayne State University), Vihren N. Kolev(Verastem (United States)), Guo Fu(Xiamen University), Jonathan A. Pachter(Verastem (United States)), David T. Weaver(University of North Carolina Health Care), Duygu Ozmadenci(University of California San Diego), Sean Uryu(Pfizer (United States)), Florian J. Sulzmaier(National Foundation for Cancer Research), Jian Li(Xiamen University), Guorong Xu(Hunan University of Science and Technology), Adam M. Mark, A. Barrie(Moores Cancer Center), Pekka Rappu(University of Turku), Michael McHale(University of California, San Diego), Elizabeth G. Kleinschmidt(Moores Cancer Center)
bioRxiv (Cold Spring Harbor Laboratory)
March 30, 2019
Cited by 21


Related Papers